Resultados de la búsqueda 291-300 of 10160 for Raised CRP

1. Oncología (médica) - Ensayos clínicos - Mayo Clinic

   Rochester, Minn. This phase III trial studies whether inotuzumab ozogamicin added to post-induction chemotherapy for patients with High-Risk B-cell Acute ...

2. Neurología - Ensayos clínicos - Mayo Clinic

   ... high (80-90%) frequency of MUC1 expression and variably high (unreported to 50%) HER2/neu (“HER2”) expression; (2) Cohort 2 focuses on primary or secondary ...

3. Neurología - Ensayos clínicos - Mayo Clinic

   ... high (80-90%) frequency of MUC1 expression and variably high (unreported to 50%) HER2/neu (“HER2”) expression; (2) Cohort 2 focuses on primary or secondary ...

4. Oncología (médica) - Ensayos clínicos - Mayo Clinic

   The current phase 3 trial seeks to improve the event-free survival (EFS) for children with high-risk neuroblastoma through early integration of promising novel ...

5. Oncología (médica) - Ensayos clínicos - Mayo Clinic

   Patients with MIBG-avid, ALK wild type (or ALK unknown) disease will be randomized to one of three arms: A) current COG recommended high-risk therapy including ...

6. Oncología (médica) - Ensayos clínicos - Mayo Clinic

   Patients with MIBG-avid, ALK wild type (or ALK unknown) disease will be randomized to one of three arms: A) current COG recommended high-risk therapy including ...

7. Cirugía - Ensayos clínicos - Mayo Clinic

   Scottsdale/Phoenix, Ariz., Rochester, Minn. The purpose of this study is to combine MRI images with histologic and genetic analysis of cancer (from blood and ...

8. Oncología (médica) - Ensayos clínicos - Mayo Clinic

   ... high (80-90%) frequency of MUC1 expression and variably high (unreported to 50%) HER2/neu (“HER2”) expression; (2) Cohort 2 focuses on primary or secondary ...

9. Mayo Clinic Digestive Diseases Physician Update - April 2025

   Page 1.

10. Neurología - Ensayos clínicos - Mayo Clinic

    ... high (80-90%) frequency of MUC1 expression and variably high (unreported to 50%) HER2/neu (“HER2”) expression; (2) Cohort 2 focuses on primary or secondary ...